Last reviewed 2026-04-20 · How we verify

GM-CSF Injectable

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Chills
• Fatigue
• Pyrexia
• Neutropenia
• Nausea
• Rash
• Diarrhoea
• Headache
• Pruritus
• Pain
• Injection Site Reaction
• Vomiting

Key clinical trials

• Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (PHASE2)
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (PHASE3)
• A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma (PHASE2)
• A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (PHASE2)
• A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (PHASE1)
• Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer (PHASE1)
• Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (PHASE1)
• A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GM-CSF Injectable CI brief — competitive landscape report
• GM-CSF Injectable updates RSS · CI watch RSS
• Rampart Health, L.L.C. portfolio CI